Metastatic Prostate Cancer incidence and prostate-specific antigen testing: new insights from the European Randomized Study of Screening for Prostate Cancer

摘要

BackgroundThe European Randomized study of Screening for Prostate Cancer (ERSPC) has shown a 21% reduction in prostate cancer (PC) mortality and a 1·6-fold increase in PC incidence with PSA-based screening (at 13 years of follow-up). We evaluated PC incidence by risk category at diagnosis across the arms in order to assess the potential impact on PC mortality.